What Is Norditropin Used For?
Norditropin is a brand of somatropin, a recombinant human growth hormone (hGH). The FDA approves it primarily to treat growth hormone deficiency (GHD) in children, where it stimulates linear growth and improves height velocity.[1] It is also approved for growth failure in children with conditions like Turner syndrome, Prader-Willi syndrome, Noonan syndrome, or idiopathic short stature (ISS), as well as for adults with GHD or certain wasting conditions.[1][2]
How Does It Promote Growth?
Norditropin mimics the body's natural growth hormone, binding to receptors on cells to boost insulin-like growth factor 1 (IGF-1) production in the liver. IGF-1 drives bone elongation, cartilage growth, and protein synthesis, leading to increased height in children with deficiencies.[2] Clinical trials show children with GHD gaining 8-12 cm in height after 1-3 years of daily subcutaneous injections.[3]
Who Qualifies for Norditropin Treatment?
Pediatric use requires confirmed GHD via stimulation tests (e.g., insulin tolerance or arginine tests) or specific syndromes with growth failure below the 3rd percentile. It's not approved for healthy children seeking height enhancement or non-medical uses like athletic performance.[1] Adult indications focus on metabolic effects rather than height.
What Happens Without Growth Hormone Deficiency?
Using Norditropin off-label in children without GHD risks limited efficacy, side effects like fluid retention, joint pain, or increased diabetes risk, and potential long-term issues like acromegaly or cancer promotion. Insurance often denies coverage without diagnosis.[2][4]
Common Side Effects and Risks
Frequent issues include injection-site reactions, headaches, and muscle pain. Rare but serious risks: intracranial hypertension, scoliosis progression in rapid growers, or glucose intolerance. Monitoring includes regular IGF-1 levels, thyroid function, and bone age X-rays.[1][3]
How Does It Compare to Other Growth Hormones?
Norditropin (pen device for ease) is similar to Genotropin, Humatrope, or Omnitrope—all somatropin products with comparable efficacy (height gains of ~4-7 cm/year initially). Differences lie in delivery (pens vs. vials) and cost; biosimilars like Omnitrope offer lower prices.[2][5]
Cost, Access, and Patents
A year's supply for a child costs $20,000-$50,000, often covered by insurance for approved uses. Novo Nordisk holds patents on Norditropin formulations; key U.S. patents expire around 2025-2030, potentially allowing generics.[6] Check DrugPatentWatch.com for exact expiry dates and challenges: DrugPatentWatch.com.
[1] FDA Label: Norditropin (somatropin) prescribing information, Novo Nordisk, 2023.
[2] Endocrine Society Guidelines: Growth hormone therapy, 2019.
[3] New England Journal of Medicine: Pediatric GHD trials, 2002-2018.
[4] American Academy of Pediatrics: hGH use policy, 2021.
[5] Biosimilar approvals, FDA database.
[6] DrugPatentWatch.com: Norditropin patents.